Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

The role of PET/CT in the modern treatment of Hodgkin lymphoma.

Author information

Affiliations

  • 1. Department of Hematology and Transplantology, Medical University of Gdańsk, Poland.
      Authors
    • Zaucha JM 1
    (1 author)
  • 2. Department of Medical Physics, Santa Croce e Carle Hospital, Cuneo, Italy.
      Authors
    • Chauvie S 2
    (1 author)
  • 3. Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland.
      Authors
    • Zaucha R 3
    (1 author)
  • 4. Department of Nuclear Medicine, Santa Croce e Carle Hospital, Cuneo, Italy.
      Authors
    • Biggii A 4
    (1 author)
  • 5. Department of Research and Clinical Innovation, A. Lacassagne Cancer Center, Nice, France.
      Authors
    • Gallamini A 5
    (1 author)

ORCIDs linked to this article

Cancer Treatment Reviews, 19 Jun 2019, 77:44-56
https://doi.org/10.1016/j.ctrv.2019.06.002 PMID: 31260900 

Review

Abstract 

Classical Hodgkin Lymphoma is distinguished from other lymphomas by its peculiar biology and heterogeneous chemosensitivity. Most of the patients respond to the standard first-line treatment and are cured, however, in selected cases, the disease relapses or remains primarily refractory. Among predictive/prognostic factors 18FDG positron emission tomography (PET), fully integrated with computed tomography (PET/CT) proved to be extremely useful in identifying patients with poor prognosis at the time of diagnosis, during and at the end of treatment. The aim of this review is to present the current role of PET/CT in cHL at staging, interim and end of therapy assessment and its ability to guide treatment with a response- and risk-adapted strategy in clinical practice. Finally, quantitative PET measurement and the concurrent use of PET with selected biomarkers are discussed.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.ctrv.2019.06.002

Citations & impact 

Impact metrics

33
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/62975198
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/62975198

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/j.ctrv.2019.06.002

Supporting
Mentioning
Contrasting
1
44
1

Article citations

Go to all (33) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Polish Lymphoma Research Group